2018
Exercise and weight loss interventions and miRNA expression in women with breast cancer
Adams BD, Arem H, Hubal MJ, Cartmel B, Li F, Harrigan M, Sanft T, Cheng CJ, Pusztai L, Irwin ML. Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Research And Treatment 2018, 170: 55-67. PMID: 29511965, PMCID: PMC6444907, DOI: 10.1007/s10549-018-4738-6.Peer-Reviewed Original ResearchConceptsBaseline body mass indexBC survivorsTumor recurrenceWeight gainWeight lossBreast cancer survivorsSerum miRNA expressionWeight loss interventionBody mass indexWeight loss trialCancer-related deathIndependent clinical trialsMiRNA expressionSix-month interventionCanonical pathwaysTop canonical pathwaysPhysical exercise trialsIngenuity Pathway AnalysisIngenuity Pathway Analysis softwareSporadic BCDevelopment of cancerLoss interventionMass indexCancer survivorsExercise trials
2017
Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
Bottai G, Diao L, Baggerly KA, Paladini L, Győrffy B, Raschioni C, Pusztai L, Calin GA, Santarpia L. Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal Of Molecular Sciences 2017, 18: 194. PMID: 28106823, PMCID: PMC5297825, DOI: 10.3390/ijms18010194.Peer-Reviewed Original ResearchConceptsEpidermal growth factorExpression profilesMessenger RNA (mRNA) expression profilesMiRNA-regulated pathwaysAvailable gene expression profilesOncostatin M signalingMesenchymal-like breast cancer cellsGene expression profilesRNA expression profilesImmune-related pathwaysPathway regulationGlobal miRNAOncogenic networksGene expressionSpecific miRNAsPathway analysisBreast cancer cellsHuman estrogen receptorTriple-negative breast cancerEMT pathwayMesenchymal transitionMiRNAMRNA dataOncostatin MCancer cells
2016
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer
Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research 2016, 76: 927-939. PMID: 26676753, PMCID: PMC4755913, DOI: 10.1158/0008-5472.can-15-2321.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancerTumor growthMiR-34a replacement therapyTNBC cell linesDifferent TNBC subtypesPromising therapeutic strategyAttenuates tumor growthHuman clinical trialsMiRNA-profiling studiesMiR-34a levelsCell linesPotent antitumorigenic effectsMiR-34a targetsHuman tumor specimensC-SrcReplacement therapyTNBC subtypesAggressive subtypeTreatment optionsClinical trialsDisease progressionEffective therapyPatient outcomesC-Src inhibitor
2011
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Jung E, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le X, Bast RC, Park S, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2011, 118: 2603-2614. PMID: 22370716, PMCID: PMC3864019, DOI: 10.1002/cncr.26565.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPositive breast cancerMiR-210 levelsBreast cancerMiR-210Cancer patientsMicroRNA expression levelsTumor presenceExpression levelsPlasma samplesBT474 cellsNeoadjuvant trastuzumab-based chemotherapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Trastuzumab-resistant breast cancer cellsMiR expression levelsTrastuzumab-based chemotherapyPathologic complete responseGrowth factor receptor 2Cancer cellsPostoperative plasma samplesPreoperative plasma samplesReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionMiR-210 expression